The study of recombinant adeno-associated virus administration in patients with Menkes Syndrome
The company Kunming Hope of Health Hospital is commencing recruitment for the clinical trial of the Recombinant Adeno-associated Virus Administration for Patients With Menkes Syndrome.
The trial officially began on the August 18, 2022 and is planned to complete on December 31, 2024.
It is a single-center, open, single-arm, non-randomized investigator-initiated trial evaluating the efficacy and safety of recombinant adeno-associated virus administration for patients with Menkes syndrome.
The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT05507996.
